17962723

Source:http://linkedlifedata.com/resource/pubmed/id/17962723

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0025202, umls-concept:C0030705, umls-concept:C0033684, umls-concept:C0132299, umls-concept:C0205210, umls-concept:C0220901, umls-concept:C0229671, umls-concept:C0441889, umls-concept:C1274040
pubmed:issue	5
pubmed:dateCreated	2007-11-26
pubmed:abstractText	It was the aim of this study to analyze the clinical value of the determination of serum S-100beta protein in high-risk melanoma patients.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8409922
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Nerve Growth Factors, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/S-100 calcium-binding protein beta..., http://linkedlifedata.com/resource/pubmed/chemical/S100 Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
pubmed:status	MEDLINE
pubmed:issn	1423-0380
pubmed:author	pubmed-author:AugeJosep MariaJM, pubmed-author:CastelTeresaT, pubmed-author:ConillCarlesC, pubmed-author:Domingo-DomènechJosepJ, pubmed-author:Garcia-AlbenizXabier AdrianXA, pubmed-author:GascónPereP, pubmed-author:JutisVV, pubmed-author:MalvehyJosepJ, pubmed-author:MelladoBegoñaB, pubmed-author:MolinaRafaelR, pubmed-author:PuigSusanaS, pubmed-author:VilellaRamonR
pubmed:copyrightInfo	Copyright (c) 2007 S. Karger AG, Basel.
pubmed:issnType	Electronic
pubmed:volume	28
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	264-72
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:17962723-Adult, pubmed-meshheading:17962723-Aged, pubmed-meshheading:17962723-Combined Modality Therapy, pubmed-meshheading:17962723-Disease-Free Survival, pubmed-meshheading:17962723-Female, pubmed-meshheading:17962723-Humans, pubmed-meshheading:17962723-Immunologic Factors, pubmed-meshheading:17962723-Interferon-alpha, pubmed-meshheading:17962723-Kaplan-Meier Estimate, pubmed-meshheading:17962723-Male, pubmed-meshheading:17962723-Melanoma, pubmed-meshheading:17962723-Middle Aged, pubmed-meshheading:17962723-Neoplasm Staging, pubmed-meshheading:17962723-Nerve Growth Factors, pubmed-meshheading:17962723-Prognosis, pubmed-meshheading:17962723-Prospective Studies, pubmed-meshheading:17962723-Recombinant Proteins, pubmed-meshheading:17962723-Risk, pubmed-meshheading:17962723-S100 Proteins, pubmed-meshheading:17962723-Skin Neoplasms, pubmed-meshheading:17962723-Survival Analysis, pubmed-meshheading:17962723-Treatment Outcome, pubmed-meshheading:17962723-Tumor Markers, Biological
pubmed:year	2007
pubmed:articleTitle	Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
pubmed:affiliation	Medical Oncology Department and Laboratory of Experimental Oncology, Hospital Clínic, Barcelona, Spain. 33884jdd@comb.es
pubmed:publicationType	Journal Article